Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / ETTX - Entasis Therapeutics to Present at the 39th Annual Cowen Healthcare Conference


ETTX - Entasis Therapeutics to Present at the 39th Annual Cowen Healthcare Conference

WALTHAM, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer, will present at the 39th Annual Cowen Healthcare Conference being held March 11-13, 2019 in Boston, Massachusetts.

Details of the presentations are below:
Event: 39th Annual Cowen Healthcare Conference
Date: March 11, 2019
Time: 2:50 – 3:20 PM ET

A live webcast of the presentation can be accessed under "Investors & Media" in the “News & Events” section of the Company's website at www.entasistx.com. An archived replay of the webcast will be available on its website for 30 days after the conference.

In addition to his presentation, Dr. Perros will be hosting 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with Company management should contact their Cowen representatives.

About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.

Entasis Company Contact    
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com

Investor Relations Contact
Lee Roth
The Ruth Group
646-536-7012
lroth@theruthgroup.com

Media Contact
Kirsten Thomas
The Ruth Group
(508) 280-6592
kthomas@theruthgroup.com

 

Stock Information

Company Name: Entasis Therapeutics Holdings Inc.
Stock Symbol: ETTX
Market: NASDAQ
Website: entasistx.com

Menu

ETTX ETTX Quote ETTX Short ETTX News ETTX Articles ETTX Message Board
Get ETTX Alerts

News, Short Squeeze, Breakout and More Instantly...